Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PCA3

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: PCA3. Displaying page 1 of 1.
    EudraCT Number: 2010-024649-61 Sponsor Protocol Number: POXY11 Start Date*: 2011-04-05
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Pilot study: performance of the Progensa PCA3 test in post-oxytocin urine specimens
    Medical condition: Healthy volunteer trial: intended indication for product is to mobilize prostate cells in urethra for PCA3 test.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033329 Oxytocin PT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012786-58 Sponsor Protocol Number: 8-79-52014-168 Start Date*: 2009-12-07
    Sponsor Name:Ipsen Pharma SAS
    Full Title: PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (P...
    Medical condition: Locally advanced or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) ES (Completed) LV (Completed) FR (Completed) NL (Completed) LT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000101-69 Sponsor Protocol Number: EGD-EC-005 Start Date*: 2013-07-04
    Sponsor Name:Astellas Pharma Europe Ltd. (APEL)
    Full Title: An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer.
    Medical condition: Patients with metastatic prostate cancer whom androgen deprivation therapy (ADT) is indicated
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002371-33 Sponsor Protocol Number: FS05-01 Start Date*: 2006-01-02
    Sponsor Name:Urologische Partnerschaft
    Full Title: Finasterid-unterstützte Diagnostik des Prostatakarzinoms bei Patienten mit BPH
    Medical condition: Adenoma of the prostate, elevated serum-PSA value
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001276-10 Sponsor Protocol Number: 69HCL18_0536 Start Date*: 2019-11-12
    Sponsor Name:Hospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation
    Full Title: Etude de faisabilité du guidage par TEP-IRM/68Ga-PSMA du traitement HIFU-focal en cas de récidive de cancer de prostate après radiothérapie - Etude PSMA
    Medical condition: Cancer de la prostate
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 03:45:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA